STOCK TITAN

LATAMED AI CORP, Financials

LMED
Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows LATAMED AI CORP, (LMED) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score pending refresh

We are recalculating LATAMED AI CORP,'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Earnings Quality Low Quality
0.99x

For every $1 of reported earnings, LATAMED AI CORP, generates $0.99 in operating cash flow (-$206K OCF vs -$207K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk
-4.8x

LATAMED AI CORP, earns $-4.8 in operating income for every $1 of interest expense (-$172K vs $36K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$0

LATAMED AI CORP, generated $0 in revenue in fiscal year 2025.

EBITDA
N/A
Net Income
-$207K
YoY+93.6%

LATAMED AI CORP, reported -$207K in net income in fiscal year 2025. This represents an increase of 93.6% from the prior year.

EPS (Diluted)
N/A

Cash & Balance Sheet

Free Cash Flow
N/A
Cash & Debt
$0

LATAMED AI CORP, held $0 in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
243,632

LATAMED AI CORP, had 243,632 shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
N/A

Capital Allocation

R&D Spending
N/A
Share Buybacks
N/A
Capital Expenditures
N/A

LMED Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Revenue $0 N/A $0 $0 $0 N/A $0 $0
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses $9K N/A $935-80.7% $5K+402.0% $967 N/A $22K-98.6% $1.5M
Operating Income -$43K N/A -$28K-40.7% -$20K-24.3% -$16K N/A -$34K+97.8% -$1.5M
Interest Expense $9K N/A $8K-10.3% $9K+9.9% $8K N/A $10K+12.3% $9K
Income Tax $0 N/A $0 $0 $0 N/A $0 $0
Net Income -$53K N/A -$36K-24.4% -$29K-19.3% -$24K N/A -$43K+97.2% -$1.5M
EPS (Diluted) N/A N/A N/A N/A N/A N/A N/A N/A

LMED Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Total Assets $7.8M $0 $0 $0 $0 $0 $0 $0
Current Assets $0 $0 $0 $0 $0 $0 $0 $0
Cash & Equivalents $0 $0 $0 $0 $0 $0 $0 $0
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $684K+8.4% $631K-4.9% $664K+5.8% $627K+4.9% $598K+4.3% $574K-11.5% $648K+7.2% $604K
Current Liabilities $684K+8.4% $631K-4.9% $664K+5.8% $627K+4.9% $598K+4.3% $574K-11.5% $648K+7.2% $604K
Long-Term Debt N/A N/A N/A N/A N/A N/A N/A N/A
Total Equity $7.1M+1231.8% -$631K+4.9% -$664K-5.8% -$627K-4.9% -$598K-4.3% -$574K+11.5% -$648K-7.2% -$604K
Retained Earnings -$29.7M-0.2% -$29.6M-0.4% -$29.5M-0.1% -$29.4M-0.1% -$29.4M-0.1% -$29.4M-3.2% -$28.5M-0.2% -$28.4M

LMED Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Operating Cash Flow -$28K+82.0% -$158K-1042.9% -$14K+6.9% -$15K+21.9% -$19K-97.8% -$10K+24.1% -$13K-10.2% -$11K
Capital Expenditures N/A N/A N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Investing Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Financing Cash Flow $28K-82.0% $158K+1042.9% $14K-6.9% $15K-21.9% $19K+97.8% $10K-24.1% $13K+10.2% $11K
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

LMED Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A N/A
Return on Equity -0.7% N/A N/A N/A N/A N/A N/A N/A
Return on Assets -0.7% N/A N/A N/A N/A N/A N/A N/A
Current Ratio 0.000.0 0.000.0 0.000.0 0.000.0 0.000.0 0.000.0 0.000.0 0.00
Debt-to-Equity 0.10+1.1 -1.000.0 -1.000.0 -1.000.0 -1.000.0 -1.000.0 -1.000.0 -1.00
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Note: Shareholder equity is negative (-$631K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

LATAMED AI CORP, (LMED) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, LATAMED AI CORP, (LMED) reported a net income of -$207K in fiscal year 2025.

LATAMED AI CORP, (LMED) generated -$206K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

LATAMED AI CORP, (LMED) had $0 in total assets as of fiscal year 2025, including both current and long-term assets.

LATAMED AI CORP, (LMED) had 243,632 shares outstanding as of fiscal year 2025.

LATAMED AI CORP, (LMED) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

LATAMED AI CORP, (LMED) had a debt-to-equity ratio of -1.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Based on fiscal year 2025 data, LATAMED AI CORP, (LMED) had $0 in cash against an annual operating cash burn of $206K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

LATAMED AI CORP, (LMED) has negative shareholder equity of -$631K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

LATAMED AI CORP, (LMED) has an earnings quality ratio of 0.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

LATAMED AI CORP, (LMED) has an interest coverage ratio of -4.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top